Pancreatic alpha-cell dysfunction contributes to the disruption of glucose homeostasis and compensatory insulin hypersecretion in glucocorticoid-treated rats

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Rafacho, Alex ^a   Gonçalves Neto, Luiz M ^a   Santos Silva, Junia C ^b   Alonso Magdalena, Paloma ^c   Merino, Beatriz ^c   Taboga, Sebastião R ^d   Carneiro, Everardo M ^b   Boschero, Antonio C ^b   Nadal, Angel ^c   Quesada, Ivan ^c  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON RECEPTOR; GLUCOCORTICOID; GLUCOSE; RECOMBINANT HUMAN INSULIN; DEXAMETHASONE; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET DISEASE; RAT; SECRETORY GRANULE; ANIMAL; BLOOD; CELL CULTURE; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG EFFECTS; HOMEOSTASIS; HYPERINSULINISM; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-SECRETING CELLS; GLUCOCORTICOIDS; HOMEOSTASIS; HYPERINSULINISM; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN RESISTANCE; MALE; RATS; RATS, WISTAR;

EID: 84899449989     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093531     Document Type: Article

References (37)

1. Ortsäter H, Sjöholm A, Rafacho A (2012) Regulation of Glucocorticoid Receptor Signaling and the Diabetogenic Effects of Glucocorticoid Excess. In State of the Art of Therapeutic Endocrinology. 1st ed. Magdeldin S, Ed. Rijeka, InTech, p. 1-28.
2. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 353: 1711-1723.
3. Schäcke H, Döcke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43.
4. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S (1992) The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci USA 89: 6035-6039.
5. Schneiter P, Tappy L (1998) Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. Am J Physiol 275: E806-E813.
6. Nicod N, Giusti V, Besse C, Tappy L (2003) Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obes Res 11:625-631 (Pubitemid 41151613)
7. Rafacho A, Quallio S, Ribeiro DL, Taboga SR, Paula FM, et al. (2010) The adaptive compensations in endocrine pancreas from glucocorticoid-treated rats are reversible after the interruption of treatment. Acta Physiol 200: 223-235.
8. Rafacho A, Abrantes JL, Ribeiro DL, Paula FM, Pinto ME, et al. (2011) Morphofunctional alterations in endocrine pancreas of short- and long-term dexamethasone-treated rats. Horm Metab Res 43: 275-281.
9. van Raalte DH, Nofrate V, Bunck MC, van Iersel T, Elassaiss Schaap J, et al. (2010) Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol 162: 729-735.
10. van Raalte DH, Ouwens DM, Diamant M (2009) Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 39: 81-93.
11. Karlsson S, Ostlund B, Myrsén-Axcrona U, Sundler F, Ahrén B (2001) Beta cell adaptation to dexamethasone-induced insulin resistance in rats involves increased glucose responsiveness but not glucose effectiveness. Pancreas 22: 148-156. (Pubitemid 32179169)
12. Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR (2009) High doses of dexamethasone induce increased beta-cell proliferation in pancreatic rat islets. Am J Physiol Endocrinol Metab 296: E681-E689.
13. Rafacho A, Marroquí L, Taboga SR, Abrantes JL, Silveira LR, et al. (2010) Glucocorticoids in vivo induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. Endocrinology 151: 85-95.
14. Wise JK, Hendler R, Felig P (1973) Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. J Clin Invest 52: 2774-2782.
15. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, et al. (2011) Chronic treatment with glucagon antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 54: 2381-2391.
16. Henquin JC, Rahier J (2011) Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 54: 1720-1725.
17. Quesada I, Tudurí E, Ripoll C, Nadal A (2008) Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 199: 5-19.
18. Cummings BP, Bremer AA, Kieffer TJ, D'Alessio D, Havel PJ (2013) Investigation of the mechanisms contributing to the compensatory increase in insulin secretion during dexamethasone-induced insulin resistance in rhesus macaques. J Endocrinol 216:207-215.
19. Jensen DH, Aaboe K, Henriksen JE, Vølund A, Holst JJ, et al. (2012) Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Diabetologia 55: 1406-1416.
20. Gromada J, Ding WG, Barg S, Renström E, Rorsman P (1997) Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflugers Arch 434: 515-524. (Pubitemid 27355170)
21. Moens K, Flamez D, Van Schravendijk C, Ling Z, Pipeleers D, et al. (1998) Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 47: 66-72. (Pubitemid 28030809)
22. Soriano S, Gonzalez A, Marroquí L, Tudurí E, Vieira E, et al. (2010) Reduced insulin secretion in protein malnourished mice is associated with multiple changes in the beta-cell stimulus-secretion coupling. Endocrinology 151: 3543-3554.
23. Marroquí L, Batista TM, Gonzalez A, Vieira E, Rafacho A, et al. (2012) Functional and structural adaptations in the pancreatic α-cell and changes in glucagon signaling during protein malnutrition. Endocrinology 153: 1663-1672.
24. Nunes EA, Gonçalves-Neto LM, Ferreira FBD, Santos C, Fernandes LC, et al. (2013) Glucose intolerance induced by glucocorticoid excess is further impaired by co-administration with β-hydroxy-β-methylbutyrate in rats. Appl Physiol Nutr Metab 38: 1137-1146.
25. Unson CG, Gurzenda EM, Merrifield RB (1989) Biological acitivities of des-His(Glu9]glucagon amide, a glucagon antagonist. Peptides 10: 1171-1177. (Pubitemid 20037265)
26. Huypens P, Ling Z, Pipeleers D, Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43: 1012-1019. (Pubitemid 30655721)
27. Montanya E, Téllez N (2009) Pancreatic remodeling: beta-cell apoptosis, proliferation and neogenesis, and the measurement of beta-cell mass and of individual beta-cell size. Methods Mol Biol 560: 137-158.
28. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM (2008) 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 51: 2003-2011.
29. Beaudry JL, D'Souza AM, Teich T, Tsushima R, Riddell MC (2013) Exogenous glucocorticoids and a high-fat diet cause severe hyperglycemia and hyperinsulinemia and limit glucose responsiveness in young male Sprague-Dawley rats. Endocrinology 154: 3197-3208.
30. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, et al. (2000) Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr 19: 29-34. (Pubitemid 30150806)
31. Marco J, Calle C, Hedo JA, Villanueva ML (1976) Enhanced glucagon secretion by pancreatic islets from prednisolone-treated mice. Diabetologia 12: 307-311.
32. Meier JJ, Ueberberg S, Korbas S, Schneider S (2011) Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass. Am J Physiol Endocrinol Metab 300: E717-E723.
33. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, et al. (2009) miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A. 106: 5813-5818.
34. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, et al. (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45: 257-261. (Pubitemid 26048675)
35. Turban S, Liu X, Ramage L, Webster SP, Walker BR, et al. (2012) Optimal elevation of β-cell 11β-hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced β-cell failure. Diabetes 61: 642-652.
36. Diederich S, Quinkler M, Mai K, Schöneshöfer M, Baehr V, et al. (2011) In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid. Horm Metab Res 43: 66-71.
37. Pereira CD, Azevedo I, Monteiro R, Martins MJ (2012) 11β- Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab 14: 869-881.